報價延遲最少15分鐘:2025/05/31 16:06 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.93 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.04/-3.44
|
|
企業價值
60.56M
|
| 資產負債 |
|
每股賬面淨值
6.93
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
251.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 16:06 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program ofthe company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |